Noxafil (posaconazole)

P3, N=664, Not yet recruiting, University of Minnesota

P=N/A, N=15, Completed, Fondazione IRCCS Policlinico San Matteo di Pavia

P1/2, N=84, Not yet recruiting, AstraZeneca | Trial completion date: Jun 2029 --> Feb 2029 | Trial primary completion date: Jun 2029 --> Feb 2029

Although co-administration of posaconazole with ruxolitinib resulted in a statistically significant increase in ruxolitinib systemic exposure, the magnitude of this interaction was clinically moderate. Although ruxolitinib dose adjustment may not be routinely required when used concomitantly with posaconazole, close monitoring for ruxolitinib-related adverse effects is recommended under this combination therapy setting.

P=N/A, N=60, Recruiting, Institute of Hematology & Blood Diseases Hospital, China

P1/2, N=84, Not yet recruiting, AstraZeneca

P2, N=40, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=36, Recruiting, Institute of Hematology & Blood Diseases Hospital, China

P=N/A, N=180, Not yet recruiting, Shang Jin Hospital of West China Hospital,Sichuan University/Chengdu Shang Jin Nan Fu Hospital; Chengdu Shang Jin Nan Fu Hospital/West China Hospital,

Caspofungin appears clinically comparable to posaconazole for PAP in AML during the induction phase, especially when azole use is contraindicated. Prospective studies are warranted to refine prophylactic strategies in the era of new AML therapies.

Abnormally increased serum CRP and TNF-α levels were decreased gradually on treatment with the nanoformulation at the end of day 8. Conclusion Local treatment of OC with buccal mucoadhesive chitosan-coated nanoparticles of posaconazole was found to be beneficial not only in reducing the overall required dosage and minimizing side effects but also in eliminating the possibility of drug interaction that is encountered during systemic therapy of posaconazole.

Safety and economic implications were evaluated based on the duration of cytopenias and hospitalization costs for Chinese patients with acute myeloid leukemia (AML) across three groups: VEN 400 mg, VEN 100 mg combined with posaconazole (POS) (VEN 100 mg + POS) and VEN 100 mg combined with VOR (VEN 100 mg + VOR). This increase in the plasma concentration of VEN may result in a longer duration of days to white blood cell (WBC) > 2000 cells/mm3 (25 vs. 13, p < 0.05) and a higher likelihood of increased hospitalization costs (140,469 vs. 73,513, p = 0.068) compared to VEN 400 mg alone. Chinese population may require further dose reduction of VEN beyond guideline recommendations when combined with VOR.